VIRTTU Biologics to Present at Biotrinity 2016 in London

April 19, 2016 – VIRTTU Biologics, a biopharmaceutical company pioneering the discovery and development of oncolytic viruses for treating cancer, today announced that it will present at the BioTrinity 2016, Europe’s leading Investment and Bio-partnering conference, on Tuesday, April 26, 2016 in London and will discuss SEPREHVIR®, VIRTTU’s Phase 2 treatment for cancer, and new generation products.

Details of VIRTTU’s presentation are as follows:


BioTrinity 2016


April 26, 2016


11.30 p.m. GMT


Lalande/Talbot room, 2nd floor Novotel London West


About VIRTTU Biologics

VIRTTU’s lead oncolytic product SEPREHVIR® has been administered to 97 patients ranging from 8 to 84 years with many different types of cancer including brain, melanoma, head and neck cancer, sarcomas, neuroblastoma and mesothelioma (a devastating lung cancer associated with asbestos exposure).  In these patients, SEPREHVIR can be administered by the route most suitable for their disease which includes systemic administration by intravenous infusion, direct intratumoral injection, and loco-regional infusion.  SEPREHVIR, which the company is interested in partnering for further development, is the first product from an active oncolytic immunotherapy platform technology.

VIRTTU's pipeline also includes new generation oncolytic immunotherapeutics. Our expert scientists have developed novel SEPREHVIR backbones with improved cancer cell killing and enhanced immune stimulation using a proprietary engineering system that streamlines their production.